Multiple Sclerosis

Noseworthy, John H.; Lucchinetti, Claudia F.; Rodriguez, Moses; Weinshenker, Brian G.

doi:10.1056/nejm200009283431307

Cited by 3,096 publications

(2,349 citation statements)

References 92 publications

Supporting

Mentioning

2,174

Contrasting

Unclassified

107

Order By: Relevance

“…Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and one of the most frequent neurological disorders in young adults (Noseworthy, Lucchinetti, Rodriguez, & Weinshenker, 2000). The generally recognized MS risk factor hypovitaminosis D (Ascherio & Munger, 2007;Hanwell & Banwell, 2011) is defined as a 25-hydroxyvitamin D (25(OH)D) concentration below 50 nmol/L and is prevalent in approximately 57% of German adults (Hintzpeter, Mensink, Thierfelder, Müller, & Scheidt-Nave, 2008).…”

Section: Introductionmentioning

confidence: 99%

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity

Miclea

Miclea²,

Pistor

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity

Miclea

Miclea²,

Pistor

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…While MS has traditionally been considered to be a T-cell-mediated disease, there is an increasing body of evidence that B cells and autoantibodies may play a pathogenic role in this disease, providing a rationale for therapeutic approaches targeting B cells and B cell derived components of the immune system. B cells and plasma cells are commonly found in active MS plaques and the presence of cerebrospinal fluidspecific antibodies (oligoclonal bands) remains a hallmark finding in the diagnosis of MS (Noseworthy et al, 2000). In addition, myelinspecific antibodies have been identified in areas of vesicular demyelination (Genain et al, 1999), suggesting that they directly promote CNS damage, at least in a subset of MS patients .…”

Section: Introductionmentioning

confidence: 99%

Antibody response in MOG35–55 induced EAE

Lalive

Molnarfi

Benkhoucha

et al. 2011

Journal of Neuroimmunology

View full text Add to dashboard Cite

Neurological deficit in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis is widely considered to be a consequence of synergistic T and B cell responses to central nervous system (CNS) antigens. We show that mice immunized with encephalitogenic myelin oligodendrocyte glycoprotein ) peptide develop significant serum levels of anti-MOG antibodies in parallel with disease progression. Furthermore, EAE mice developed antibodies against DNA and RNA, a serological hallmark observed in autoimmune diseases such as systemic lupus erythematosus. The presence of anti-nucleic responsive B cells and antibodies during EAE may highlight a previously unappreciated mechanism in the pathogenesis of CNS autoimmunity.

show abstract

“…Multiple sclerosis (MS) is a complex, chronic inflammatory, progressive neurologic disorder that is the leading cause of non‐traumatic neurologic disability in young adults 1, 2. Its aetiology is unknown, but as for many complex diseases, environmental, genetic and immunologic factors have all been implicated 1.…”

Section: Introductionmentioning

confidence: 99%

“…Its aetiology is unknown, but as for many complex diseases, environmental, genetic and immunologic factors have all been implicated 1. The most common age of onset for MS is 20–40 years, and the disease tends to be more common in women 1, 2. MS affects individuals at a productive time in their lives, has a negative impact on quality of life 3 and is associated with significant economic burden 4.…”

Section: Introductionmentioning

confidence: 99%

Long‐term epidemiology of multiple sclerosis in the N orthern S eville D istrict

et al. 2015

View full text Add to dashboard Cite

ObjectivesComprehensive epidemiologic data for multiple sclerosis (MS) in Spain are limited. The aim of this study was to collect epidemiologic data on MS in the Northern Seville District of Spain.Materials and methodsThis longitudinal study identified possible MS cases every year from nine centres between 1 January 1991 and 31 December 2011. Patients with a confirmed diagnosis of MS were included. MS data prior to enrolment were collected retrospectively from clinical records and prospectively during quarterly follow‐up clinic visits. Variables included age at onset, age at diagnosis, treatment, follow‐up duration, number of visits, number of relapses, change in the number of relapses over time and Expanded Disability Status Scale score. The incidence and prevalence of MS rate were calculated.ResultsOverall, 156 patients with MS were identified (111 females; mean follow‐up 7.5 years). Most patients had relapsing‐remitting MS (73.7%); primary progressive disease was less frequent than secondary disease (10.9% vs 15.4%). The yearly incidence of MS was 4.6 per 100,000, and the prevalence at 31 December 2011 was 90.2 per 100,000.ConclusionsThe annual MS incidence rate in this southern region of Spain was higher than previously reported rates in Spanish studies.

show abstract

Multiple Sclerosis

Cited by 3,096 publications

References 92 publications

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity

Antibody response in MOG35–55 induced EAE

Long‐term epidemiology of multiple sclerosis in the N orthern S eville D istrict

Contact Info

Product

Resources

About